[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525399":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":19,"studyPopulation":11,"armGroups":20,"interventions":32,"overallOfficials":41,"centralContacts":45,"locations":50,"responsibleParty":69,"collaborators":71,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":11,"eligibilityCriteria":79,"healthyVolunteers":76,"sex":80,"minAge":81,"maxAge":11,"enrollmentInfo":82,"targetDuration":11,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":11,"overallStatus":53,"whyStopped":11,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",null,"through study completion; an average of 1 year.",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"NON_RANDOMIZED","SINGLE_GROUP","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":11},"NONE","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document\n* Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds\n* Patients seen at Pain Management Center at MD Anderson Cancer Center\n* Patient ages greater or equal to 18 years but less than or equal to 85 years\n\nExclusion Criteria:\n\n* Patients with cognitive dysfunction\n* Patient with recent history (\\\u003C6 months) of drug or alcohol abuse\n* Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection\n* Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy",[21,27],{"label":22,"type":23,"description":24,"interventionNames":25},"Treatment Group","EXPERIMENTAL","Group 1 will receive neuromodulation.",[26],"Device: Abbott® DRG \u002F Abbott®\u002FMedtronic® SCS",{"label":28,"type":23,"description":29,"interventionNames":30},"Control Group","Group 2 will not receive neuromodulation.",[31],"Other: Control Group",[33,38],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":11},"DEVICE","Abbott® DRG \u002F Abbott®\u002FMedtronic® SCS","Participants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future.",[22],{"type":6,"name":28,"description":39,"armGroupLabels":40,"otherNames":11},"Participants will not receive any intervention",[28],[42],{"name":43,"affiliation":5,"role":44},"Saba Javed, M D","PRINCIPAL_INVESTIGATOR",[46],{"name":43,"role":47,"phone":48,"phoneExt":11,"email":49},"CONTACT","(713) 792-9530","sjaved@mdanderson.org",[51],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":60,"coordinates":61},"Point",[62,63],-95.36327,29.76328,{"lat":63,"lon":62},[66,68],{"name":43,"role":47,"phone":67,"phoneExt":11,"email":49},"713-792-9530",{"name":43,"role":44,"phone":11,"phoneExt":11,"email":11},{"type":70,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[72],{"name":73,"class":6},"Foundation for Anesthesia Education and Research","100525399","exploring-the-benefit-of-neuromodulation-in-treating-chemo-induced-peripheral-neuropathy-using-peripheral-neuropathy-markers-meissners-corpuscles-and-epidermal-nerve-fiber-density-and-sensory-testing-quantitative-sensory-and-gait-testing-a-single-center-feasibility-study-100525399",false,"NCT06121232","Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document\n* Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds\n* Patients seen at Pain Management Center at MD Anderson Cancer Center\n* Patient ages greater or equal to 18 years but less than or equal to 85 years\n\nExclusion Criteria\n\n* Patients with cognitive dysfunction\n* Patient with recent history (\\\u003C6 months) of drug or alcohol abuse\n* Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection\n* Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy","ALL","18 Years",{"count":83,"type":84},24,"ESTIMATED","INTERVENTIONAL",[87],"NA","To learn if a process called neuromodulation can help to improve pain due to CIP",[90],"Neuropathy;Peripheral","2026-09-30",{"date":93,"type":94},"2026-10-02","ACTUAL",{"date":96,"type":94},"2023-11-02",{"date":98,"type":84},"2028-06-01",{"name":5,"class":6},1]